Alzheimer’s Disease (AD) is the most common type of dementia and its burden is expected to grow substantially owing to aging of the population, improving the diagnostic accuracy of AD is critical. Neuroimaging presents immense potential for developing reliable biomarkers that can be viewed in the living brain. neuropathological features on which the definitive diagnosis of AD relies, seen at post-mortem in the brains of AD patients, are general atrophy of the cortex, neuron and synapse loss, extracellular plaques composed of insoluble ?-amyloid (A?) and Intraneuronal neurofibrillary tangles (NFTs) consisting of hyperphosphorylated tau. Neuroimaging examinations are an essential part of the diagnostic investigation of dementia. These examinations are important not only to identify non-AD pathological processes that can lead to cognitive decline. Neuroimaging evaluation is based on nonspecific features such as atrophy, which is a late feature in the progression of the disease.